|
| 37624932 | Classification of Brain Tumors by Nanopore Sequencing of Cell-Free DNA from Cerebrospinal Fluid. | Clin Chem | 2024 |
| 35868257 | DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients. | Neuro Oncol | 2023 |
| 37720395 | Epigenetic profiling reveals a strong association between lack of 5-ALA fluorescence and <i>EGFR</i> amplification in <i>IDH</i>-wildtype glioblastoma. | Neurooncol Pract | 2023 |
| 37609137 | Epigenetic neural glioblastoma enhances synaptic integration and predicts therapeutic vulnerability. | bioRxiv | 2023 |
| 37877968 | Grade 3 meningioma survival and recurrence outcomes in an international multicenter cohort. | J Neurosurg | 2023 |
| 37608807 | <i>hGFAP</i>-mediated <i>GLI2</i> overexpression leads to early death and severe cerebellar malformations with rare tumor formation. | iScience | 2023 |
| 37501103 | Mitochondrial DNA mutations in Medulloblastoma. | Acta Neuropathol Commun | 2023 |
| 37219662 | A Carboxy-terminal Smarcb1 Point Mutation Induces Hydrocephalus Formation and Affects AP-1 and Neuronal Signalling Pathways in Mice. | Cell Mol Neurobiol | 2023 |
| 37287693 | A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorial <i>ZFTA-</i>fused ependymoma. | Neurooncol Adv | 2023 |
| 36990436 | Isolated extradural sacrococcygeal ependymoma mimicking teratoma in a 5-year-old boy. | Klin Padiatr | 2023 |
| 37450044 | Recurrent atypical teratoid/rhabdoid tumors (AT/RT) reveal discrete features of progression on histology, epigenetics, copy number profiling, and transcriptomics. | Acta Neuropathol | 2023 |
| 37277823 | Group-specific cellular metabolism in Medulloblastoma. | J Transl Med | 2023 |
| 37407554 | The tumor suppressor CREBBP and the oncogene MYCN cooperate to induce malignant brain tumors in mice. | Oncogenesis | 2023 |
| 36966138 | Genomic characterization of DICER1-associated neoplasms uncovers molecular classes. | Nat Commun | 2023 |
| 36999511 | Update on quality assurance in neuropathology: Summary of the round robin trials on <i>TERT</i> promoter mutation, <i>H3-3A</i> mutation, 1p/19q codeletion, and <i>KIAA1549::BRAF</i> fusion testing in Germany in 2020 and 2021. | Clin Neuropathol | 2023 |
| 36860191 | Targeted anticonvulsive treatment of IDH-wildtype glioblastoma based on DNA methylation subclasses. | Neuro Oncol | 2023 |
| 36786841 | Correction to: Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification. | Acta Neuropathol | 2023 |
| 36694344 | Preclinical patient-derived modeling of castration-resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease. | Mol Oncol | 2023 |
| 36519297 | Analysing cerebrospinal fluid with explainable deep learning: From diagnostics to insights. | Neuropathol Appl Neurobiol | 2023 |
| 36582072 | Generation of new transgenic SMARCA4-deficient mouse models results in neuromuscular weakness and paralysis of limbs. | Brain Pathol | 2023 |
| 36715306 | Risk prediction in early childhood sonic hedgehog medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than 2 subgroups. | Neuro Oncol | 2023 |
| 36543154 | Cauda Equina Neuroendocrine Tumors: Distinct Epithelial Neuroendocrine Neoplasms of Spinal Origin. | Am J Surg Pathol | 2023 |
| 36437415 | Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification. | Acta Neuropathol | 2023 |
| 36709315 | G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells. | Radiat Oncol | 2023 |
| 36534132 | The spectrum of morphological findings in pediatric central nervous system MN1-fusion-positive neuroepithelial tumors. | Childs Nerv Syst | 2023 |
| 36866403 | Atypical neurofibromas reveal distinct epigenetic features with proximity to benign peripheral nerve sheath tumor entities. | Neuro Oncol | 2023 |
| 36734226 | Adult intracranial ependymoma-relevance of DNA methylation profiling for diagnosis, prognosis, and treatment. | Neuro Oncol | 2023 |
| 36459208 | Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts. | Acta Neuropathol | 2023 |
| 36527335 | Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification. | Neuropathol Appl Neurobiol | 2023 |
| 36928815 | Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology. | Nat Med | 2023 |
| 34309720 | Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling. | Childs Nerv Syst | 2022 |
| 35511473 | DNA methylation subclass receptor tyrosine kinase II (RTK II) is predictive for seizure development in glioblastoma patients. | Neuro Oncol | 2022 |
| 35380708 | Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. | Neuro Oncol | 2022 |
| 35700707 | Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. | Cancer Cell | 2022 |
| 35641267 | Recurrent Mandibular Giant Cell Lesion in Neurofibromatosis Type 1: Second Hit Mutation on the <i>NF1</i> Gene in the Osseous Lesion. | Anticancer Res | 2022 |
| 35446794 | SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome. | Am J Surg Pathol | 2022 |
| 36443295 | DNA methylation-based classification of sinonasal tumors. | Nat Commun | 2022 |
| 36163595 | Genetic and epigenetic profiling identifies two distinct classes of spinal meningiomas. | Acta Neuropathol | 2022 |
| 33908610 | Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial. | Neuro Oncol | 2022 |
| 35190934 | Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. | J Neurooncol | 2022 |
| 35318328 | Single-cell transcriptomics identifies potential cells of origin of MYC rhabdoid tumors. | Nat Commun | 2022 |
| 34980502 | Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. | Eur J Cancer | 2022 |
| 35307892 | Updates in the classification of ependymal neoplasms: The 2021 WHO Classification and beyond. | Brain Pathol | 2022 |
| 35213080 | A new amplicon-based gene panel for next generation sequencing characterization of meningiomas. | Brain Pathol | 2022 |
| 34878655 | Machine learning models predict the primary sites of head and neck squamous cell carcinoma metastases based on DNA methylation. | J Pathol | 2022 |
| 35195346 | ALK inhibition as a salvage therapy for a relapsed unclassifiable sarcomatous CNS tumor with EML4/ALK fusion in an infant. | Pediatr Blood Cancer | 2022 |
| 35322202 | Disruption of GMNC-MCIDAS multiciliogenesis program is critical in choroid plexus carcinoma development. | Cell Death Differ | 2022 |
| 34674226 | Primary central nervous system sarcoma with DICER1 mutation-treatment results of a novel molecular entity in pediatric Peruvian patients. | Cancer | 2022 |
| 32633004 | Ependymoma relapse goes along with a relatively stable epigenome, but a severely altered tumor morphology. | Brain Pathol | 2021 |
| 33768604 | Cauda equina paragangliomas express HOXB13. | Neuropathol Appl Neurobiol | 2021 |